Business ActivitiesOur Business
Since its inception, Human Life CORD has focused on the potential of the umbilical cord, the tissue that connects the placenta to the fetus, as a source of cell therapy. It aims to obtain mesenchymal stromal cells extracted from the umbilical cord and commercialize this as regenerative medicine products for patients and their families in need as soon as possible. This project is based on the approval of patent, technology, and know-how gained through inventions related to umbilical cord research by Dr. Tokiko Nagamura, Associate Professor of the Cord Blood/Cord Bank/Somatic Stem Cell Research Area at the Institute of Medical Science, the University of Tokyo (IMSUT CORD).
Through our activities, with the cord of life from the umbilical cord, we will support the hope to live of patients suffering from diseases that could not be helped by conventional medical treatment.
About Mesenchymal Stromal Cells (MSCs)
Mesenchymal Stromal Cells (MSCs) are multipotent cells found in various tissues throughout the human body, including bone marrow, adipose tissue and umbilical cord. MSCs play a critical role in the regulation of immune responses and tissue repair due to their ability to migrate to sites of inflammation and injury. The therapeutic effects of MSCs are mediated by a combination of factors, including cytokines and exosomes secreted from MSCs and direct cell-to-cell interactions. These properties have made MSCs a promising candidate for regenerative medicine and cell-based therapies.
Benefits of using the umbilical cord
Unique integrated supply chain
Under a partnership with external organizations and corporations, including the distribution of umbilical cords by IMSUT CORD, research collaboration with the Institute of Medical Science, the University of Tokyo (IMSUT), and contracts with Roto Pharmaceutical Co., Ltd., and Alfressa Co., Ltd., Human Life CORD has established a system for managing and operating a comprehensive supply chain from obtaining the raw material (umbilical cord) to the manufacturing of cellular products and distribution to facilities.
Overview of our supply chain for umbilical cord-derived mesenchymal cell products:
Until a single umbilical cord reaches the patient as a mesenchymal stromal cell product
IMSUT-HLC cell processing facilities:
From September 2021, a cell processing manufacturing facility has been operating at IMSUT. The facility can produce master cells and a certain level of products.
Stakeholders
R&D, manufacturing, and commercialization of umbilical cord-derived mesenchymal stromal cell products by Human Life CORD are promoted in cooperation with various organizations and companies who support our mission.
Business Activities
Back to Top Page